Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer

Who May Qualify: - Patients must be at least 18 years old - diagnosed by tissue sample (biopsy-confirmed) prostate cancer - Clinical or pathologic stages T1c-T3b, Nx or N0-1, M0-1 (American Joint Committee on Cancer \[AJCC\] criteria 8th edition \[Ed\]) - Planned definitive dose radiotherapy to the prostate or prostate bed - Eastern Cooperative Oncology Group (ECOG) performance status 0-2 assessed within 90 days of enrollment - Patients must sign Institutional Review Board (IRB) approved study specific willing to sign a consent form - Patients must complete all required pre-entry tests within the specified time frames - Patients must be able to start treatment (radiation) within 180 days of study registration - In case of confusion about the eligibility or ineligibility of an individual patient, the principal investigator (PI) can be used as the arbiter and a note to file will be added to the subject's regulatory binder to document outcome Who Should NOT Join This Trial: - Previous pelvic radiation \> 5 Gy - Planned delivery of radiotherapy to pelvic lymph nodes - Planned delivery of brachytherapy of the prostate - Active rectal diverticulitis, Crohn's disease affecting the rectum, or ulcerative colitis (non-active diverticulitis and Crohn's disease not affecting the rectum are allowed) - Prior hip replacement or penile implant - Major medical, addictive, or psychiatric illness which in the investigator's opinion, will prevent the consent process, completion of the treatment and/or interfere with follow-up. (consent by legal authorized representative is not permitted for this study) - Indwelling or intermittent urinary catheter use Always talk to your doctor about whether this trial is right for you.